Niox Group PLC AGM Statement
22 Maggio 2024 - 8:00AM
RNS Regulatory News
RNS Number : 3503P
Niox Group PLC
22 May 2024
NIOX GROUP
PLC
("NIOX"
or the "Company"
and, together with its subsidiaries, the
"Group")
AGM
Statement
Oxford, UK - 22 May 2024: NIOX
Group plc (AIM: NIOX), a medical device company focused on point of
care asthma diagnosis and management, is holding its Annual General
Meeting today at the Hayakawa Building, Edmund Halley Road, Oxford
Science Park. Oxford OX4 4GB.
Trading Update
We are pleased to report that our
business has continued to perform strongly in the year to date, in
line with management expectations.
In January 2024, NIOX settled
returns claims amounting to £0.4m in relation to the discontinued
business. The unaudited cash balance as at 30 April 2024 was £23.7m
(31 December 2023: £19.9m), with no bank borrowings.
NIOX expects to give a trading
update in relation to the six months ended 30 June 2024 around the
middle of July.
Contacts:
|
NIOX
Ian Johnson, Executive
Chairman
Michael Roller, Chief Financial
Officer
|
Tel: +44 (0) 1865 405
560
|
|
|
|
|
Singer Capital Markets
(Nominated Adviser and Broker)
Aubrey Powell / Jen Boorer / James
Todd
|
Tel: +44 (0) 20 7496
3000
|
|
|
|
|
Investec Bank plc (Joint Broker)
Edward Knight / Bruce Garrow / Lydia
Zychowska
|
Tel: +44 (0) 20 7597
4000
|
About NIOX
Our mission is to improve asthma
diagnosis and management by greater patient access to FeNO testing.
Asthma is one of the biggest healthcare issues globally with 340
million sufferers, many of whom are undiagnosed or are
misdiagnosed. The Group is engaged in the design, development, and
commercialisation of medical devices for the measurement of FeNO, a
precise biomarker for asthma. Our market leading device, NIOX
VERO®, is increasingly recognised by
healthcare professionals as an important tool to improve the
diagnosis and management of asthma. NIOX VERO® is also the device of choice by leading clinical
research organisations for respiratory studies.
NIOX provides products and services
via its direct sales organisation and extensive distributor network
in 50 countries. For more information, please visit
www.niox.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
AGMGZGZKVMKGDZM
Grafico Azioni Niox (LSE:NIOX)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Niox (LSE:NIOX)
Storico
Da Gen 2024 a Gen 2025
